WK Cancer Treatement Center

Clinical Trials

Myelodysplastic Syndromes (MDS) (low/int-1 risk) & Transfusional Iron Overload


To assess the efficacy and safety of iron chelation therapy with a single agent compared to placebo in patients with myelodysplastic syndromes (MDS) (low/int-1 risk) and transfusional iron overload.


  • Male and Female patients at least 18 years of age
  • Must weigh between 35-135 kg
  • Low or intermediate risk MDS, confirmed by a bone marrow
  • Hematologically stable • History of transfusion of 15-75 PRBC units
  • Anticipated to be transfused with at least 8 units of PRBCs annually


  • Screening Period: up to 30 days
  • Study visits: every 4 weeks
  • Eye & Ear exam required during screening

Interested in Volunteering for the Study?

If you would like more information about this study, please call us at (318) 212-8671.